Recruiting
InvestigationalNo placebo
A study to evaluate the effect of zigakibart in adults with IgA nephropathy
InvestigationalNo placebo
- Substances:ZIGAKIBART
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:ZIGAKIBART
Find therapies in clinical trials near you – page 6
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
586 trials match your criteria
Recruiting
Interstitial lung disease+1
RecruitingInvestigational
A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease
Investigational
- Disease:Interstitial lung diseasePulmonary hypertension
- Substances:Treprostinil
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Treprostinil
Recruiting
Renal disorder+1
RecruitingRegistered drugNo placebo
A study to evaluate the safety of ADX-038 in patients with complement-mediated kidney disease
Registered drugNo placebo
- Disease:Renal disorderImmune-mediated renal disorder
- Substances:ADX-038TETANUS TOXOID+25
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:ADX-038
Recruiting
Secondary progressive multiple sclerosis
RecruitingInvestigational
A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis
Investigational
- Disease:Secondary progressive multiple sclerosis
- Substances:Remibrutinib
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Remibrutinib
Recruiting
Polyneuropathy
RecruitingRegistered drugNo placebo
A study to evaluate the safety and effectiveness of nucresiran and vutrisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy
Registered drugNo placebo
- Disease:Polyneuropathy
- Substances:Vutrisiran
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Vutrisiran
Recruiting
Breast cancer metastatic
RecruitingRegistered drugNo placebo
Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer
Registered drugNo placebo
- Disease:Breast cancer metastatic
- Substances:AbemaciclibElacestrant
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
Recruiting
Interstitial lung disease
RecruitingRegistered drug
Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease
Registered drug
- Disease:Interstitial lung disease
- Substances:Belimumab
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Belimumab
Recruiting
Pulmonary arterial hypertension
RecruitingInvestigationalNo placebo
A Study of ROC-101 Hydrochloride for Patients with Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease
InvestigationalNo placebo
- Disease:Pulmonary arterial hypertension
- Substances:ROC-101 HYDROCHLORIDE
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:ROC-101 HYDROCHLORIDE
Recruiting
Cardiac amyloidosis
RecruitingInvestigational
A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy
Investigational
- Disease:Cardiac amyloidosis
- Substances:–
Countries:Italy
Italy- Participants:18–64 years · 65+ years
Recruiting
Bacterial vaginosis
RecruitingRegistered drugNo placebo
A study comparing furazidin and clindamycin for women with bacterial vaginosis
Registered drugNo placebo
- Disease:Bacterial vaginosis
- Substances:Clindamycin Phosphate
Countries:Italy
Italy- Participants:18–64 years
- Substances:Clindamycin Phosphate
Recruiting
Non-small cell lung cancer
RecruitingRegistered drugNo placebo
Study of STK-012 Alone and Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Registered drugNo placebo
- Disease:Non-small cell lung cancer
- Substances:CarboplatinPembrolizumab+1
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Carboplatin
Recruiting
Non-small cell lung cancer stage IIIA+2
RecruitingRegistered drugNo placebo
Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment
Registered drugNo placebo
- Disease:Non-small cell lung cancer stage IIIANon-small cell lung cancer stage IIIB+1
- Substances:CarboplatinCisplatin+9
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Carboplatin